Effect of carbazochrome sodium sulfonate on refractory chronic prostatitis. (25th June 2014)

• Record Type: Journal Article
• Authors: Oh‐oka, Hitoshi; Yamada, Tetsuo; Noto, Hiromitsu; Umeyama, Tomokazu; Kadekawa, Katsumi; Ashitomi, Katsuhiro; Nishijima, Saori; Sugaya, Kimio
• Is Part Of: International journal of urology. Volume 21:Number 11(2014)
• Page Start: 1162
• Page End: 1166
• Publication Date: 2014-06-25
• Subjects: capillary permeability -- carbazochrome -- chronic prostatitis -- urine occult blood; Urology -- Periodicals; Genitourinary organs -- Periodicals; Urologic Diseases -- Periodicals; 616.6005
• DOI: 10.1111/iju.12533
• Languages: English
• ISSNs: 0919-8172

Abstract

Abstract : Objectives: To study the effect of carbazochrome sodium sulfonate, an agent that reduces capillary permeability, on refractory chronic prostatitis. Methods: Patients with prostatitis refractory to at least 8 weeks of routine therapy and with urinalysis positive for microhematuria were considered for the present study. In addition to their prior therapy, the patients received carbazochrome at a dose of 30 mg three times a day. The severity of pain (score 0–10), daytime and night‐time frequency, international prostate symptom score, global self‐assessment, urine occult blood positivity, and adverse events were assessed after 4 and 8 weeks of treatment, and compared with baseline findings. Results: A total of 50 patients (mean age 68.6 ± 8.5 years) were evaluable. The pain score decreased significantly from 3.2 ± 2.1 at baseline to 1.7 ± 1.4 after 4 weeks of treatment and to 1.1 ± 1.8 after 8 weeks. Daytime and night‐time frequency, storage symptoms, post‐micturition symptoms, and urine occult blood positivity also significantly improved. More than 36% of the patients gave a global self‐assessment rating of "improved" or "better" after both 4 and 8 weeks of treatment. Mild adverse events occurred in three patients; one had nausea and two developed drug rash. Conclusions: Carbazochrome seems to effectively improve pain as well as storage and post‐micturition symptoms in patients with refractory chronic prostatitis.